S 
Shenzhen Mindray Bio-Medical Electronics Co 300760.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
181.10
-1.66%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥33.28bn
FY2016FY2025
Net income
CN¥8.14bn
FY2016FY2025
Free cash flow
CN¥8.11bn
FY2016FY2025
Shareholders' equity
CN¥38.09bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥33.28bn | CN¥36.73bn | CN¥34.93bn | CN¥30.37bn | CN¥25.27bn | CN¥21.03bn | CN¥16.56bn | CN¥13.75bn | CN¥11.17bn | CN¥9.03bn |
| Gross profit | CN¥20.07bn | CN¥22.96bn | CN¥22.16bn | CN¥19.41bn | CN¥16.30bn | CN¥13.57bn | CN¥10.76bn | CN¥9.13bn | CN¥7.47bn | CN¥5.75bn |
| Research and development | CN¥3.58bn | CN¥3.67bn | CN¥3.43bn | CN¥2.92bn | CN¥2.52bn | CN¥1.87bn | CN¥1.47bn | CN¥1.27bn | CN¥1.02bn | CN¥989.7m |
| Operating income | CN¥9.94bn | CN¥13.11bn | CN¥13.07bn | CN¥10.99bn | CN¥9.07bn | CN¥7.46bn | CN¥5.38bn | CN¥4.28bn | CN¥2.99bn | CN¥1.42bn |
| Net income | CN¥8.14bn | CN¥11.67bn | CN¥11.58bn | CN¥9.61bn | CN¥8.00bn | CN¥6.66bn | CN¥4.68bn | CN¥3.72bn | CN¥2.59bn | CN¥1.60bn |
| Diluted earnings per share | 6.71 | 9.63 | 9.56 | 7.93 | 6.59 | 5.48 | 3.85 | 3.41 | 2.36 | 1.32 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥59.27bn | CN¥56.64bn | CN¥47.94bn | CN¥46.75bn | CN¥38.10bn | CN¥33.49bn | CN¥25.67bn | CN¥21.62bn | CN¥14.44bn | CN¥12.97bn |
| Cash and short-term investments | — | CN¥16.64bn | CN¥18.79bn | CN¥27.15bn | CN¥15.36bn | CN¥15.86bn | CN¥14.27bn | CN¥11.54bn | CN¥5.30bn | CN¥5.02bn |
| Total liabilities | CN¥16.26bn | CN¥15.89bn | CN¥14.59bn | CN¥14.75bn | CN¥11.13bn | CN¥10.20bn | CN¥7.07bn | CN¥6.45bn | CN¥7.78bn | CN¥8.37bn |
| Debt | — | CN¥298.5m | CN¥294.9m | CN¥236.5m | CN¥237.2m | — | CN¥2.0m | CN¥6.0m | CN¥1.87bn | CN¥3.58bn |
| Shareholders' equity | CN¥38.09bn | CN¥35.86bn | CN¥33.09bn | CN¥31.98bn | CN¥26.95bn | CN¥23.28bn | CN¥18.58bn | CN¥15.15bn | CN¥6.62bn | CN¥4.52bn |
| Shares outstanding | 1,212m | 1,211m | 1,211m | 1,211m | 1,215m | 1,216m | 1,217m | 1,090m | 1,095m | 1,212m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥10.14bn | CN¥12.43bn | CN¥11.06bn | CN¥12.14bn | CN¥9.00bn | CN¥8.87bn | CN¥4.72bn | CN¥4.03bn | CN¥3.30bn | CN¥3.04bn |
| Capital spending | −CN¥2.04bn | −CN¥1.96bn | −CN¥2.69bn | −CN¥1.92bn | −CN¥1.40bn | −CN¥1.18bn | −CN¥776.9m | −CN¥678.3m | −CN¥466.7m | −CN¥413.5m |
| Free cash flow | CN¥8.11bn | CN¥10.47bn | CN¥8.37bn | CN¥10.23bn | CN¥7.60bn | CN¥7.69bn | CN¥3.94bn | CN¥3.36bn | CN¥2.83bn | CN¥2.63bn |
| Dividends paid | −CN¥5.61bn | −CN¥8.74bn | −CN¥10.67bn | −CN¥4.23bn | −CN¥3.04bn | −CN¥1.82bn | −CN¥1.22bn | −CN¥949.2m | −CN¥611.3m | −CN¥6.52bn |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥9.39bn | CN¥8.35bn | CN¥7.45bn | CN¥8.99bn | CN¥8.51bn | CN¥8.24bn | CN¥7.24bn | CN¥8.95bn |
| Gross profit | CN¥5.63bn | CN¥5.17bn | CN¥4.07bn | CN¥5.57bn | CN¥5.08bn | CN¥5.15bn | CN¥3.83bn | CN¥5.62bn |
| Operating income | CN¥3.22bn | CN¥2.79bn | CN¥1.05bn | CN¥2.94bn | CN¥2.87bn | CN¥3.05bn | CN¥1.02bn | CN¥3.52bn |
| Net income | CN¥2.47bn | CN¥2.33bn | CN¥565.7m | CN¥2.50bn | CN¥2.44bn | CN¥2.63bn | CN¥1.03bn | CN¥3.08bn |
| Diluted earnings per share | 2.04 | 1.92 | 0.47 | 2.06 | 2.01 | 2.17 | 0.85 | 2.54 |
| Cash from operations | — | — | — | CN¥3.35bn | CN¥2.43bn | CN¥1.49bn | — | CN¥2.58bn |
| Capital spending | −CN¥463.0m | −CN¥600.0m | −CN¥510.0m | −CN¥510.0m | −CN¥519.0m | −CN¥497.0m | −CN¥541.0m | −CN¥506.0m |
| Free cash flow | — | — | — | CN¥2.84bn | CN¥1.91bn | CN¥997.0m | — | CN¥2.07bn |
| Total assets | CN¥60.79bn | CN¥59.61bn | CN¥59.27bn | CN¥59.27bn | CN¥58.77bn | CN¥58.36bn | CN¥56.64bn | CN¥57.60bn |
| Cash and short-term investments | — | — | — | CN¥17.52bn | CN¥17.09bn | CN¥17.71bn | CN¥16.64bn | CN¥17.66bn |
| Debt | CN¥248,664 | CN¥272,785 | CN¥4.1m | CN¥125.0m | CN¥10.1m | CN¥6.0m | CN¥5.7m | CN¥6.1m |
| Shareholders' equity | CN¥40.56bn | CN¥40.11bn | CN¥38.09bn | CN¥39.30bn | CN¥39.04bn | CN¥38.59bn | CN¥35.86bn | CN¥37.09bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 3.1% | 9.6% | 15.3% |
| Operating income | -3.3% | 5.9% | 26.3% |
| Net income | -5.4% | 4.1% | 24.5% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 61.5% | 62.5% | 63.0% | 63.5% |
| Operating margin | 32.9% | 34.8% | 35.0% | 32.8% |
| Net margin | 28.3% | 30.3% | 30.6% | 28.8% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Price to earnings | 28.4 | 26.5 | 30.4 | 39.8 | 57.8 | 77.8 | 47.3 | 32.0 |
| Price to sales | 6.9 | 8.4 | 10.1 | 12.6 | 18.3 | 24.6 | 13.4 | 8.7 |
Dividends and splits
Per share, in the currency the company pays
Paid for 7 years. Last went ex-dividend on 28 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 1.56 | 4.63 | 7.21 | 8.80 | 3.50 | 2.50 | 1.50 | 1.00 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.